(Q38180998)

30 August 2017

title

Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache (English)

1 reference

30 August 2017

1 reference

1 reference

Stephen J Peroutka

1

1 reference

30 August 2017

language of work or name

1 reference

1 June 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

237-244

1 reference

Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

CGRP may play a causative role in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Randomized, controlled trial of telcagepant for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

CGRP receptor antagonists: an expanding drug class for acute migraine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Emerging treatment for chronic migraine and refractory chronic migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Elevated sympathetic nervous activity in mice deficient in alphaCGRP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Role of calcitonin gene-related peptide in hypertension-induced renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Endogenous alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Plasma concentrations of calcitonin gene-related peptide increase during haemodialysis: relation to blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Plasma concentrations of calcitonin gene-related peptide in fluid overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Calcitonin gene-related peptide and other neuropeptides in the plasma of patients with soft tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Elevation of plasma CGRP and SP levels in orthopedic patients with fracture neck of femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Levels of vasodilators (SP, CGRP) and vasoconstrictor (NPY) peptides in early human burns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Migraine and obesity: epidemiology, mechanisms, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

The association of obesity with episodic and chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Episodic migraine and obesity and the influence of age, race, and sex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0083-4

10.1007/S40259-014-0083-4

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference